Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BlackRock's IBIT has accumulated $8.9 billion in inflows this year, ranking fourth among global ETFs

BlackRock's IBIT has accumulated $8.9 billion in inflows this year, ranking fourth among global ETFs

金色财经金色财经2025/05/21 13:33
Show original

According to The Block, BlackRock's IBIT Bitcoin ETF has accumulated a net inflow of $8.9 billion this year, ranking fourth among global ETFs year-to-date. Over the past month, the fund has absorbed $6.5 billion in inflows, with assets under management reaching $66.9 billion, ranking fourth after VOO, VTI, and SPLG. In 2025, the total net inflow of U.S. spot Bitcoin ETFs amounted to $7.6 billion, with $7.4 billion flowing in over the past month.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

US Stock Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) enters the US stock market, shares drop over 10% after opening

According to Jinse Finance, Retension Pharmaceuticals (RTSN.US) debuted on the US stock market on Friday and fell over 10% to $10.77 at press time, with an IPO price of $12. Retension Pharmaceuticals is a US-based clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core investigational drug, RTN-001, is a new generation phosphodiesterase 5 (PDE5) inhibitor, primarily targeting patients with uncontrolled or resistant hypertension, and is currently undergoing a Phase IIb clinical trial. This drug works by enhancing nitric oxide signaling in blood vessels to promote vasodilation and lower blood pressure. The exclusive global development license comes from French pharmaceutical giant Sanofi (SNY.US).

智通财经•2026/10/09 16:36